Group 1 - The Hang Seng Index fell by 1.07%, down 287 points, closing at 26,669 points, while the Hang Seng Tech Index decreased by 1.09% [1] - Gold stocks continued their recent upward trend, with New York gold prices surpassing $4,000; Zijin Mining International rose by 5.98%, Chifeng Jilong Gold increased by over 14%, and Shandong Gold gained 7.56% [1] Group 2 - Xinjiang Xin Mining (03833) surged over 19%, with its stock price nearly doubling after returning to A-shares, owning four nickel-copper mines [2] - Jinli Permanent Magnet (06680) rose over 6%, with institutions optimistic about the rare earth sector's valuation and performance [2] - Shanghai Electric (02727) increased by over 4% following a key breakthrough in the compact fusion energy project BEST in Hefei, Anhui [2] - Heyu-B (02256) climbed over 8% to reach a historical high, with the upcoming launch of Pimiatin expected to provide ongoing sales revenue [2] Group 3 - Yiming Anke-B (01541) rose over 7% after submitting an application for the Phase III clinical trial of IMM2510 [3] Group 4 - Botai Carlink (02889) increased over 19%, collaborating with SenseTime to promote AI applications in smart connected vehicles [4] - Changfeng Pharmaceutical (02652) debuted with a high opening of 218.64%, later rising over 180%, focusing on inhalation technology and inhalation drugs [4] Group 5 - China Cosco Shipping Energy Transportation (01138) fell over 3.7%, as OPEC+ production increases were significantly lower than previously reported, raising market concerns about oil transportation demand [5] Group 6 - Cryptocurrency-related stocks experienced significant declines, with Boya Interactive (00434) dropping over 8% as Bitcoin's plunge affected the crypto market [6]

Group 1: Hong Kong Stock Market Highlights - Jinli Permanent Magnet (06680) rose over 5%, with institutions optimistic about valuation and performance in the rare earth sector [1] - Heyu-B (02256) increased by more than 7%, as the upcoming launch of Pimiatin is expected to provide continuous sales revenue [1] - Sa Sa International (00178) saw a rise of over 6%, with a 8.4% year-on-year increase in revenue for the second fiscal quarter [1] - Gold stocks continued their recent upward trend, with Chifeng Jilong Gold Mining (06693) up over 14% and Zijin Mining International (02259) up over 7% [1] - Xinjiang Xin Mining (03833) surged over 17%, with the company announcing a near doubling of stock price after its return to A-shares [1] Group 2: U.S. Stock Market Highlights - AMD (AMD.US) rose 3.83% after announcing a 6 GW computing power agreement with OpenAI for future AI infrastructure [3] - Trilogy Metals (TMQ.US) skyrocketed 211% following the U.S. government's announcement to acquire a 10% stake in the company [3] - AppLovin (APP.US) increased by 7.64%, amid reports of an SEC investigation regarding its advertising practices [3] - Ford Motor Company (F.US) fell 6.14% due to a significant fire at a key production facility, expected to halt operations until next year [4] - Soluna Holdings (SLNH.US) surged 12.78%, reporting an increase in mining capacity from 526 PH/s in August to 658 PH/s in September [4]

（文章来源：每日经济新闻） 每经AI快讯，10月8日，港股和誉-B(02256.HK)早盘涨超8%，截至发稿，涨8.2%，报19.4港元，成交额 5846.51万港元。 ...

招商证券国际发表报告称，和誉开发的匹米替尼作为全球疗效最优CSF-1R小分子，即将在中美两地上 市，给公司带来持续销售分成。该行认为默克对该分子寄予厚望，有望在全球做到接近15亿美元高峰的 销售收入。花旗此前则表示，公司估值仅反映其两款后期候选药物匹米替尼及依帕戈替尼价值，其具高 授权潜力的差异化创新药则尚未被市场充分认可。 和誉-B(02256)早盘涨超8%，截至发稿，涨8.2%，报19.4港元，成交额5846.51万港元。 ...

招商证券国际发表报告称，和誉开发的匹米替尼作为全球疗效最优CSF-1R小分子，即将在中美两地上 市，给公司带来持续销售分成。该行认为默克对该分子寄予厚望，有望在全球做到接近15亿美元高峰的 销售收入。花旗此前则表示，公司估值仅反映其两款后期候选药物匹米替尼及依帕戈替尼价值，其具高 授权潜力的差异化创新药则尚未被市场充分认可。 智通财经APP获悉，和誉-B(02256)早盘涨超8%，截至发稿，涨8.2%，报19.4港元，成交额5846.51万港 元。 ...

Core Viewpoint - The report from China Merchants Securities Hong Kong initiates coverage on HeYue-B (02256) with a "Buy" rating, estimating a fair equity value of HKD 21 billion and a target price of HKD 32.5 for the next 12 months, highlighting the company's long-term growth potential and efficient small molecule development capabilities [1] Group 1: Product Development and Market Potential - HeYue's developed drug, Pimitinib, is expected to be launched in both China and the U.S., providing continuous sales revenue through profit-sharing [1] - The company is actively targeting two significant gene families, FGFR and KRAS, with FGFR4 as a late-stage clinical asset poised to become a new targeted small molecule in liver cancer [1] - The global sales peak for Pimitinib is projected to reach USD 1.5 billion, providing sustained cash flow for HeYue [1] Group 2: Clinical Advancements and Pipeline - HeYue has demonstrated the best efficacy globally for TGCT in the development of CSF-1R inhibitors, with superior safety and response rates compared to similar molecules [1] - The company has received over USD 150 million in cash from its collaboration with Merck, including milestone payments and sales revenue sharing, marking a significant achievement for a Chinese biotech firm in global commercialization [1] - HeYue has a robust pipeline with 22 candidate drugs, including 12 in clinical stages and 10 in preclinical stages, showcasing its leading recognition of frontier targets and clinical development capabilities [3] Group 3: Focus on FGFR and RAS Targets - The company has been deeply engaged in the FGFR target area for ten years, focusing on selective FGFR4 inhibitors and FGFR2/3 inhibitors, addressing unmet needs in liver and gastric cancers [2] - The selective FGFR4 inhibitor, Ipagotinib, is currently in critical Phase III clinical trials, potentially becoming the first approved selective inhibitor targeting FGFR4 globally [2] - HeYue is also developing early-stage molecules targeting G12D and pan-RAS, which will enhance its offerings in precision oncology [2]

Core Viewpoint - The report from China Merchants Securities Hong Kong initiates coverage on HeYue-B (02256) with a "Buy" rating, estimating a fair equity value of HKD 21 billion and a target price of HKD 32.5 for the next 12 months, highlighting the company's long-term growth potential and efficient small molecule development capabilities [1] Group 1: Product Development and Market Potential - HeYue's developed drug, Pimitinib, is positioned as the most effective CSF-1R small molecule globally and is set to launch in both China and the U.S., promising ongoing sales revenue for the company [1] - The company is actively targeting two significant families of important targets, FGFR and KRAS, with FGFR4 as a late-stage clinical asset expected to become a new targeted small molecule in the liver cancer field [1] - The global sales peak for Pimitinib is projected to reach USD 1.5 billion, providing a continuous cash flow for HeYue, with the drug being a key asset in Merck's pipeline [1] Group 2: Clinical Advancements and Pipeline - HeYue has demonstrated the best efficacy globally for TGCT in the development of CSF-1R inhibitors, with safety and response rates surpassing similar molecules [1] - The company has established a robust pipeline with 22 candidate drugs, including 12 in clinical stages and 10 in preclinical stages, showcasing its leading recognition of frontier targets and developing clinical capabilities [3] - The selective FGFR4 inhibitor, currently in pivotal Phase III trials, targets advanced liver cancer patients with FGF19 overexpression, marking a potential first in the global market if successful [2] Group 3: Strategic Focus on Targeted Therapies - The company has been focusing on the FGFR target for a decade, with a deep layout in selective FGFR4 inhibitors and FGFR2/3 inhibitors, addressing unmet needs in liver and gastric cancers [2] - The ongoing research on RAS targets, including early-stage molecules for G12D and pan-RAS, is expected to enhance the company's offerings in precision oncology [2] - The development of next-generation FGFR inhibitors and oral PD-L1 small molecules is anticipated to exceed market expectations through better data disclosure and potential business development transactions [3]

智通财经APP讯，和誉-B(02256)发布公告，本公司于2025年9月29日根据首次公开发售后购股权计划授 出 634.35万份购股权(购股权)予本公司的三名董事(董事)及若干雇员(合称"购股权承授人")，惟须待购股 权承授人接纳方可作实。 本公司于2025年9月29日根据2019年股权激励计划授出460.64万份受限制股份单位(受限制股份单位)予本 公司的若干雇员(受限制股份单位承授人)，惟须待受限制股份单位承授人接纳方可作实。 ...

格隆汇9月29日丨和誉-B(02256.HK)公告，公司于2025年9月29日根据首次公开发售后购股权计划授出 6,343,508份购股权予公司的三名董事及若干雇员，惟须待购股权承授人接纳方可作实。公司于2025年9 月29日根据2019年股权激励计划授出4,606,372份受限制股份单位予公司的若干雇员，惟须待受限制股份 单位承授人接纳方可作实。 ...

本公司于2025年9月29日根据2019年股权激励计划授出460.64万份受限制股份单位(受限制股份单位)予本 公司的若干雇员(受限制股份单位承授人)，惟须待受限制股份单位承授人接纳方可作实。 和誉-B(02256)发布公告，本公司于2025年9月29日根据首次公开发售后购股权计划授出634.35万份购股 权(购股权)予本公司的三名董事(董事)及若干雇员(合称"购股权承授人")，惟须待购股权承授人接纳方可 作实。 ...